Genoptix pockets $17.3M in early venture round

San Diego-based Genoptix has raised $17.3 million in a "series 1-D" round of venture capital. Genoptix provides laboratory services to hematologists and oncologists who are managing blood and bone marrow malignancies. Chicago Growth Partners joined existing investors Enterprise Partners, Alliance Technology Ventures, Tullis-Dickerson, U.S. Trust's Excelsior Venture Partners III, and Lotus Bioscience Investment Holdings in this round of financing.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.